1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Tibsovo Gets A Win In AML Following Servier Takeover

 
• By Alaric DeArment

Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.

Acute myeloid leukemia a 3d-Render
Servier announced results from the Phase III AGILE study of Tibsovo in IDH1-mutant AML • Source: Shutterstock

Les Laboratoires Servier SAS has added to a string of incremental wins for the drug Tibsovo (ivosidenib) since the company bought the rights from Agios Pharmaceuticals, Inc. near the end of 2020, with new positive topline Phase III results in acute myeloid leukemia (AML), though it will be entering a field with steep competition.

Paris-based Servier said 2 August that topline results of AGILE showed that Tibsovo combined with Bristol Myers Squibb Company’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.